Login to Your Account

Clinic roundup

Friday, December 13, 2013
Celator Pharmaceuticals Inc., of Ewing, N.J., said independent data and safety monitoring board for the company’s Phase III study comparing CPX-351 (cytarabine/daunorubicin) liposome injection to the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3 ) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia should continue as planned without any modifications.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription